Skip to Main Content Skip to Main Content

HSC Medicine, Dentistry and Healthcare Sciences Current Awareness Bulletins: Big 4 Journals

Big 4 Journals current awareness bulletin

Frequency: Weekly

Links to articles in the current and previous 2 issues of this bulletin are displayed below.

To receive email notifications about new issues of this bulletin, please email: richard.fallis@healthcarelibrary.qub.ac.uk

This bulletin is based on the equivalent bulletin produced by Bodleian Health Care Libraries:

30th September 2024

The BMJ: 30th September 2024

The impact of increasing temperatures due to climate change on infectious diseases

Recommendations on recording harms in randomised controlled trials of behaviour change interventions

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline

Switching from inhaled to intravenous general anaesthesia

JAMA: 1st October 2024, 332(13)

Balloon angioplasty vs medical management for intracranial artery stenosis (BASIS)

Diagnosis, risk stratification, and treatment of pericarditis: a review

Low-dose triple-pill vs standard-care protocols for hypertension treatment in Nigeria

Tranexamic acid in patients undergoing liver resection (HeLiX)

The Lancet: 5th October 2024, 404(10460)

Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY)

Hypothyroidism (review)

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18)

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor (TiNivo-2)

WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines

New England Journal of Medicine: 3rd October 2024, 391(13)

Aggressive lymphoma after CD19 CAR T-cell therapy

Avoiding rash decisions (clinical problem-solving)

Prolonged grief disorder (clinical practice review)

Reactivation of SOX17 program as immune-evasion mechanism in early colorectal cancer development

Standard or extended lymphadenectomy for muscle-invasive bladder cancer

Tirzepatide for the treatment of obstructive sleep apnea and obesity

Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women

23rd September 2024

The BMJ: 23rd-29th September 2024

The case for patient involvement in medical curriculum development

Donanemab: conflicts of interest found in FDA committee that approved new Alzheimer’s drug

Heterogeneous effects of Medicaid coverage on cardiovascular risk factors

Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C)

The physician associates becoming doctors

Preventing future deaths: what have we learnt from reports into preventable fatalities?

JAMA: 24th September 2024, 332(12)

Continuation vs discontinuation of renin-angiotensin system inhibitors before major noncardiac surgery (Stop-or-Not)

Potassium supplementation and prevention of atrial fibrillation after cardiac surgery (TIGHT K)

Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations

Renal cell carcinoma: a review

The Lancet: 28th September-4th October 2024, 404(10459)

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)

Endovascular management of acute stroke

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

Lipoprotein(a) and cardiovascular disease

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671)

New England Journal of Medicine: 26th September 2024, 391(12)

Gene therapy with fidanacogene elaparvovec in adults with hemophilia B

Neuroleptic malignant syndrome

Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis

Results after four years of screening for prostate cancer with PSA and MRI

Ziresovir in hospitalized infants with respiratory syncytial virus infection

16th September 2024

The BMJ: 16th-22nd September 2024

Acute aortic syndrome

Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis

Cumulative live birth rate of a blastocyst versus cleavage stage embryo transfer policy during in vitro fertilisation in women with a good prognosis: multicentre randomised controlled trial

Doctor suicide: “All I could see were tasks mounting, appointments being booked, and people constantly knocking on my door”

The importance of the day of embryo transfer during in vitro fertilisation

Management of atrial fibrillation in older adults

Optimising inhaled therapy for patients with asthma

JAMA: 17th September 2024, 332(11)

Comparison of no-test telehealth and in-person medication abortion

Risankizumab for ulcerative colitis: two randomized clinical trials

The Lancet: 21st-27th September 2024, 404(10458)

Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet)

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5)

Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children

Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies

New England Journal of Medicine: 19th September 2024, 391(11)

Axatilimab in recurrent or refractory chronic graft-versus-host disease

Community-based cluster-randomized trial to reduce opioid overdose deaths

Long-term oxygen therapy for 24 or 15 hours per day in severe hypoxemia

Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia

Primary central nervous system vasculitis